4jnm: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Discovery of Potent and Efficacious Urea-containing Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors with Reduced CYP2C9 Inhibition Properties== | ==Discovery of Potent and Efficacious Urea-containing Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors with Reduced CYP2C9 Inhibition Properties== | ||
<StructureSection load='4jnm' size='340' side='right' caption='[[4jnm]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='4jnm' size='340' side='right'caption='[[4jnm]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4jnm]] is a 2 chain structure with sequence from [ | <table><tr><td colspan='2'>[[4jnm]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JNM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4JNM FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1LJ:1-[(6-AMINOPYRIDIN-3-YL)METHYL]-3-[4-(PHENYLSULFONYL)PHENYL]UREA'>1LJ</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1LJ:1-[(6-AMINOPYRIDIN-3-YL)METHYL]-3-[4-(PHENYLSULFONYL)PHENYL]UREA'>1LJ</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4jnm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4jnm OCA], [https://pdbe.org/4jnm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4jnm RCSB], [https://www.ebi.ac.uk/pdbsum/4jnm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4jnm ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/NAMPT_HUMAN NAMPT_HUMAN] Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway (By similarity). | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 22: | Line 20: | ||
==See Also== | ==See Also== | ||
*[[Phosphoribosyltransferase|Phosphoribosyltransferase]] | *[[Phosphoribosyltransferase 3D structures|Phosphoribosyltransferase 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: Bair | [[Category: Bair KW]] | ||
[[Category: Bauer | [[Category: Bauer P]] | ||
[[Category: Baumeister | [[Category: Baumeister T]] | ||
[[Category: Buckmelter AJ]] | |||
[[Category: Buckmelter | [[Category: Caligiuri M]] | ||
[[Category: Caligiuri | [[Category: Clodfelter KH]] | ||
[[Category: Clodfelter | [[Category: Dragovich PS]] | ||
[[Category: Dragovich | [[Category: Fu B]] | ||
[[Category: Fu | [[Category: Gunzner-Toste J]] | ||
[[Category: Gunzner-Toste | [[Category: Han B]] | ||
[[Category: Han | [[Category: Ho Y]] | ||
[[Category: Ho | [[Category: Kley N]] | ||
[[Category: Kley | [[Category: Liederer B]] | ||
[[Category: Liederer | [[Category: Lin J]] | ||
[[Category: Lin | [[Category: Mukadam S]] | ||
[[Category: Mukadam | [[Category: O'Brien T]] | ||
[[Category: Oh | [[Category: Oh A]] | ||
[[Category: Reynolds | [[Category: Reynolds DJ]] | ||
[[Category: Sharma | [[Category: Sharma G]] | ||
[[Category: Skelton | [[Category: Skelton N]] | ||
[[Category: Smith | [[Category: Smith CC]] | ||
[[Category: Wang | [[Category: Wang W]] | ||
[[Category: Wang | [[Category: Wang Z]] | ||
[[Category: Xiao | [[Category: Xiao Y]] | ||
[[Category: Yuen | [[Category: Yuen P]] | ||
[[Category: Zak | [[Category: Zak M]] | ||
[[Category: Zhang | [[Category: Zhang L]] | ||
[[Category: Zhao | [[Category: Zhao G]] | ||
[[Category: Zheng | [[Category: Zheng X]] | ||
Revision as of 14:25, 24 November 2022
Discovery of Potent and Efficacious Urea-containing Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors with Reduced CYP2C9 Inhibition PropertiesDiscovery of Potent and Efficacious Urea-containing Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors with Reduced CYP2C9 Inhibition Properties
Structural highlights
FunctionNAMPT_HUMAN Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway (By similarity). Publication Abstract from PubMedPotent, reversible inhibition of the cytochrome P450 CYP2C9 isoform was observed in a series of urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. This unwanted property was successfully removed from the described inhibitors through a combination of structure-based design and medicinal chemistry activities. An optimized compound which did not inhibit CYP2C9 exhibited potent anti-NAMPT activity (17; BC NAMPT IC50=3nM; A2780 antiproliferative IC50=70nM), good mouse PK properties, and was efficacious in an A2780 mouse xenograft model. The crystal structure of this compound in complex with the NAMPT protein is also described. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Gunzner-Toste J, Zhao G, Bauer P, Baumeister T, Buckmelter AJ, Caligiuri M, Clodfelter KH, Fu B, Han B, Ho YC, Kley N, Liang X, Liederer BM, Lin J, Mukadam S, O'Brien T, Oh A, Reynolds DJ, Sharma G, Skelton N, Smith CC, Sodhi J, Wang W, Wang Z, Xiao Y, Yuen PW, Zak M, Zhang L, Zheng X, Bair KW, Dragovich PS Bioorg Med Chem Lett. 2013 Jun 15;23(12):3531-8. doi: 10.1016/j.bmcl.2013.04.040., Epub 2013 Apr 25. PMID:23668988[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||